CN112004543A - 包含细菌菌株的组合物 - Google Patents

包含细菌菌株的组合物 Download PDF

Info

Publication number
CN112004543A
CN112004543A CN201980026687.7A CN201980026687A CN112004543A CN 112004543 A CN112004543 A CN 112004543A CN 201980026687 A CN201980026687 A CN 201980026687A CN 112004543 A CN112004543 A CN 112004543A
Authority
CN
China
Prior art keywords
present
cells
compositions
seq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980026687.7A
Other languages
English (en)
Chinese (zh)
Inventor
多梅尼科·潘兹卡
艾米·贝丝·霍尔特
苏阿德·艾哈迈德
安娜·埃托尔
伊姆克·伊丽莎白·马尔德
菲利普·科威
艾玛·拉夫缇斯
艾玛·伊丽莎白·克莱尔·汉尼斯
黛尔芬·路易丝·克劳黛特·劳特卡里
奥雷利·帕斯卡·帕特里夏·库蒂里耶梅拉德
玛格丽特·英克斯特·黛尔德
马西里奥·阿德里亚尼
玛丽亚·克里斯托弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4D Pharma Research Ltd
Original Assignee
4D Pharma Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1804384.4A external-priority patent/GB201804384D0/en
Priority claimed from GBGB1809953.1A external-priority patent/GB201809953D0/en
Priority claimed from GBGB1811900.8A external-priority patent/GB201811900D0/en
Priority claimed from GBGB1812378.6A external-priority patent/GB201812378D0/en
Priority claimed from GBGB1813423.9A external-priority patent/GB201813423D0/en
Priority claimed from GBGB1813444.5A external-priority patent/GB201813444D0/en
Priority claimed from GBGB1816834.4A external-priority patent/GB201816834D0/en
Priority claimed from GBGB1817641.2A external-priority patent/GB201817641D0/en
Priority claimed from GBGB1901199.8A external-priority patent/GB201901199D0/en
Priority claimed from GBGB1901218.6A external-priority patent/GB201901218D0/en
Priority claimed from GBGB1901993.4A external-priority patent/GB201901993D0/en
Priority claimed from GBGB1901992.6A external-priority patent/GB201901992D0/en
Application filed by 4D Pharma Research Ltd filed Critical 4D Pharma Research Ltd
Publication of CN112004543A publication Critical patent/CN112004543A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Rheumatology (AREA)
CN201980026687.7A 2018-03-19 2019-03-19 包含细菌菌株的组合物 Pending CN112004543A (zh)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
GBGB1804384.4A GB201804384D0 (en) 2018-03-19 2018-03-19 Compositions
GB1804384.4 2018-03-19
EP18178350 2018-06-18
GBGB1809953.1A GB201809953D0 (en) 2018-06-18 2018-06-18 Compositions
EP18178350.7 2018-06-18
GB1809953.1 2018-06-18
GBGB1811900.8A GB201811900D0 (en) 2018-07-20 2018-07-20 Compositions comprising bacterial strains
GB1811900.8 2018-07-20
GBGB1812378.6A GB201812378D0 (en) 2018-07-30 2018-07-30 Compositions comprising bacterial strains
GB1812378.6 2018-07-30
GB1813444.5 2018-08-17
GB1813423.9 2018-08-17
GBGB1813423.9A GB201813423D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GBGB1813444.5A GB201813444D0 (en) 2018-08-17 2018-08-17 Compositions
GB1816834.4 2018-10-16
GBGB1816834.4A GB201816834D0 (en) 2018-10-16 2018-10-16 Compositions
GB1817641.2 2018-10-29
GBGB1817641.2A GB201817641D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GBGB1901199.8A GB201901199D0 (en) 2019-01-29 2019-01-29 Compositions comprising bacterial strains
GB1901199.8 2019-01-29
GB1901218.6 2019-01-29
GBGB1901218.6A GB201901218D0 (en) 2019-01-29 2019-01-29 Compositions
GBGB1901993.4A GB201901993D0 (en) 2019-02-13 2019-02-13 Compositions
GB1901993.4 2019-02-13
GBGB1901992.6A GB201901992D0 (en) 2019-02-13 2019-02-13 Compositions comprising bacterial strains
GB1901992.6 2019-02-13
PCT/EP2019/056894 WO2019180051A1 (en) 2018-03-19 2019-03-19 Compositions comprising bacterial strains

Publications (1)

Publication Number Publication Date
CN112004543A true CN112004543A (zh) 2020-11-27

Family

ID=65955185

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980026687.7A Pending CN112004543A (zh) 2018-03-19 2019-03-19 包含细菌菌株的组合物
CN201980020532.2A Pending CN111886018A (zh) 2018-03-19 2019-03-19 组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980020532.2A Pending CN111886018A (zh) 2018-03-19 2019-03-19 组合物

Country Status (25)

Country Link
US (3) US11419931B2 (enExample)
EP (3) EP4046644A1 (enExample)
JP (3) JP2021518414A (enExample)
KR (2) KR102578117B1 (enExample)
CN (2) CN112004543A (enExample)
AU (2) AU2019239048B2 (enExample)
BR (2) BR112020019008A2 (enExample)
CA (2) CA3094297A1 (enExample)
CY (1) CY1125104T1 (enExample)
DK (1) DK3768284T3 (enExample)
ES (1) ES2908826T3 (enExample)
HR (1) HRP20220368T1 (enExample)
HU (1) HUE058151T2 (enExample)
IL (2) IL277422A (enExample)
LT (1) LT3768284T (enExample)
MA (1) MA52128A (enExample)
MD (1) MD3768284T2 (enExample)
MX (2) MX2020009733A (enExample)
PL (1) PL3768284T3 (enExample)
RS (1) RS63090B1 (enExample)
SG (2) SG11202009254YA (enExample)
SI (1) SI3768284T1 (enExample)
SM (1) SMT202200111T1 (enExample)
TW (2) TW202003001A (enExample)
WO (2) WO2019180051A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021113500A2 (en) * 2019-12-03 2021-06-10 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
KR102461645B1 (ko) * 2020-10-20 2022-11-01 전남대학교산학협력단 플라젤린 융합 단백질을 포함하는 비알코올성 지방간질환 또는 대사증후군 예방 또는 치료용 조성물
EP4384194A4 (en) * 2021-10-08 2025-07-16 Univ Iowa State Res Found Inc USE OF DOPAMINE-PRODUCING PRODUCTS TO INCREASE VACCINE EFFECTIVENESS
CN113999923B (zh) * 2021-11-25 2024-05-14 上海金翌生物科技有限公司 小柳-原田综合症标志微生物及其应用
CN115287243B (zh) * 2022-04-15 2023-06-06 集美大学 一株变形假单胞菌flgK基因沉默菌株及其构建方法
JPWO2024096122A1 (enExample) * 2022-11-04 2024-05-10
KR102878250B1 (ko) 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085520A1 (en) * 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
CN111246866A (zh) * 2017-08-10 2020-06-05 4D制药研究有限公司 包含细菌菌株的组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20080025977A1 (en) 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
EP1958647A1 (en) 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
EP2133092B1 (en) 2007-03-19 2015-12-09 Morishita Jintan Co., Ltd. Oral vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
EP2486134B1 (en) * 2009-10-06 2014-01-08 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
EP2731572B1 (en) 2011-07-13 2021-04-07 Pharmaxis Ltd. Improvements relating to delivery devices
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
FR2989002B1 (fr) 2012-04-10 2015-05-15 Beepratte Lab Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique
WO2014043593A2 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10480002B2 (en) * 2014-02-12 2019-11-19 Transalgae Israel Ltd. Algal based edible vaccines
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520502D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (fr) * 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085520A1 (en) * 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
CN111246866A (zh) * 2017-08-10 2020-06-05 4D制药研究有限公司 包含细菌菌株的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
周庭银等: "《血流感染实验诊断与临床诊治 第2版》", 31 May 2014 *
翁心华等: "《翁心华疑难感染病和发热病例精选与临床思维 2017版》", 30 September 2017 *

Also Published As

Publication number Publication date
US20210138058A1 (en) 2021-05-13
EP3768285A1 (en) 2021-01-27
JP2021518414A (ja) 2021-08-02
RS63090B1 (sr) 2022-04-29
JP2023100747A (ja) 2023-07-19
US20210169950A1 (en) 2021-06-10
JP2021518129A (ja) 2021-08-02
WO2019180000A1 (en) 2019-09-26
MA52128A (fr) 2021-01-27
SG11202009254YA (en) 2020-10-29
WO2019180051A1 (en) 2019-09-26
PL3768284T3 (pl) 2022-04-11
AU2019239048A1 (en) 2020-11-05
AU2019239048B2 (en) 2022-07-21
SMT202200111T1 (it) 2022-05-12
CY1125104T1 (el) 2024-02-16
ES2908826T3 (es) 2022-05-04
IL277421A (en) 2020-11-30
CN111886018A (zh) 2020-11-03
MX2020009733A (es) 2022-10-27
IL277421B (en) 2022-04-01
MD3768284T2 (ro) 2022-06-30
US11419931B2 (en) 2022-08-23
EP4046644A1 (en) 2022-08-24
CA3094297A1 (en) 2019-09-26
EP3768284B1 (en) 2022-01-05
SI3768284T1 (sl) 2022-04-29
DK3768284T3 (da) 2022-03-07
CA3094139A1 (en) 2019-09-26
BR112020019008A2 (pt) 2020-12-29
AU2019238358A1 (en) 2020-10-08
US11857614B2 (en) 2024-01-02
MX2020009736A (es) 2021-01-08
TW202003000A (zh) 2020-01-16
SG11202009259VA (en) 2020-10-29
US20220257745A1 (en) 2022-08-18
HUE058151T2 (hu) 2022-07-28
KR102578117B1 (ko) 2023-09-12
BR112020018818A2 (pt) 2021-05-04
KR20210003096A (ko) 2021-01-11
HRP20220368T1 (hr) 2022-06-24
LT3768284T (lt) 2022-04-11
TW202003001A (zh) 2020-01-16
EP3768284A1 (en) 2021-01-27
IL277422A (en) 2020-11-30
KR20200134255A (ko) 2020-12-01

Similar Documents

Publication Publication Date Title
US11419931B2 (en) Compositions comprising bacterial strains
IL259138A (en) Preparations containing bacterial strains
US20230048366A1 (en) Combination therapy for treating or preventing cancer
US20230277602A1 (en) Combination therapy for treating or preventing cancer
KR20210046007A (ko) 박테리아 균주를 포함하는 조성물
US20210060094A1 (en) Combination therapy for treating or preventing cancer
US20210060093A1 (en) Combination therapy for treating or preventing cancer
OA20782A (en) Compositions comprising bacterial strains.
von Goetze Direct induction of TGF-β signaling by the gut commensal Anaeroplasma
OA20162A (en) Combination therapy for treating or preventing cancer
OA20165A (en) Combination therapy for treating or preventing cancer.
OA20163A (en) Combination therapy for treating or preventing cancer.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201127